George A Makar1, John H Holmes, Yu-Xiao Yang. 1. Affiliations of authors: Division of Gastroenterology (GAM, Y-XY) and Center for Clinical Epidemiology and Biostatistics (GAM, JHH, Y-XY), Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.
Abstract
BACKGROUND: Laboratory data suggest a role of angiotensin II in the pathogenesis of colorectal cancer (CRC). Whether angiotensin converting enzyme inhibitor (ACE-I) and/or angiotensin receptor blocker (ARB) use reduces the risk of colorectal neoplasia remains unclear. Given their widespread use, we sought to determine whether exposure to these agents would have a secondary benefit on CRC incidence. METHODS: A nested case-control study was conducted using EPIC's General Practice Research Database (1987-2002). The study cohort consisted of hypertensive patients. Case patients were those diagnosed with CRC after the diagnosis of hypertension. Each case patient was matched to up to 10 control subjects on age, sex, and both calendar year and duration of follow-up using incidence density sampling. The association between CRC and ACE-I/ARB exposure was assessed with conditional logistic regression. All statistical tests were two-sided. RESULTS: Two thousand eight-hundred forty-seven case patients were matched with 28239 control subjects. The adjusted odds ratios (ORs) of CRC were 0.84 (95% confidence interval [CI] = 0.72 to 0.98; P = .03) for or more years of ACE-I/ARB therapy and 0.75 (95% CI = 0.58 to 0.97; P = .03) for 5 or more years of exposure. The strength of this association increased with high-dose exposure (OR = 0.53; 95% CI = 0.35 to 0.79; P = .003 for ≥3 years of high-dose exposure). Among patients receiving antihypertensive medications, the association with long-term therapy was no longer statistically significant for ≥5 years), but the benefit of high-dose therapy remained (OR = 0.59; 95% CI = 0.39 to 0.89; P = .01 for ≥3 years of high-dose exposure). CONCLUSIONS: Long-term/high dose exposure to ACE-Is/ARBs may be associated with a decreased incidence of CRC.
BACKGROUND: Laboratory data suggest a role of angiotensin II in the pathogenesis of colorectal cancer (CRC). Whether angiotensin converting enzyme inhibitor (ACE-I) and/or angiotensin receptor blocker (ARB) use reduces the risk of colorectal neoplasia remains unclear. Given their widespread use, we sought to determine whether exposure to these agents would have a secondary benefit on CRC incidence. METHODS: A nested case-control study was conducted using EPIC's General Practice Research Database (1987-2002). The study cohort consisted of hypertensivepatients. Case patients were those diagnosed with CRC after the diagnosis of hypertension. Each case patient was matched to up to 10 control subjects on age, sex, and both calendar year and duration of follow-up using incidence density sampling. The association between CRC and ACE-I/ARB exposure was assessed with conditional logistic regression. All statistical tests were two-sided. RESULTS: Two thousand eight-hundred forty-seven case patients were matched with 28239 control subjects. The adjusted odds ratios (ORs) of CRC were 0.84 (95% confidence interval [CI] = 0.72 to 0.98; P = .03) for or more years of ACE-I/ARB therapy and 0.75 (95% CI = 0.58 to 0.97; P = .03) for 5 or more years of exposure. The strength of this association increased with high-dose exposure (OR = 0.53; 95% CI = 0.35 to 0.79; P = .003 for ≥3 years of high-dose exposure). Among patients receiving antihypertensive medications, the association with long-term therapy was no longer statistically significant for ≥5 years), but the benefit of high-dose therapy remained (OR = 0.59; 95% CI = 0.39 to 0.89; P = .01 for ≥3 years of high-dose exposure). CONCLUSIONS: Long-term/high dose exposure to ACE-Is/ARBs may be associated with a decreased incidence of CRC.
Authors: H T Sørensen; J H Olsen; L Mellemkjaer; A Marie; F H Steffensen; J K McLaughlin; J A Baron Journal: Cancer Date: 2000-07-01 Impact factor: 6.860
Authors: Caroline Happold; Thierry Gorlia; L Burt Nabors; Sara C Erridge; David A Reardon; Christine Hicking; Martin Picard; Roger Stupp; Michael Weller Journal: J Neurooncol Date: 2018-02-08 Impact factor: 4.130
Authors: Phyo T Htoo; Til Stürmer; Michele Jonsson-Funk; Virginia Pate; Ross J Simpson; Jennifer L Lund Journal: Epidemiology Date: 2019-11 Impact factor: 4.822
Authors: Tianyi Huang; Elizabeth M Poole; A Heather Eliassen; Olivia I Okereke; Laura D Kubzansky; Anil K Sood; John P Forman; Shelley S Tworoger Journal: Int J Cancer Date: 2016-03-25 Impact factor: 7.396
Authors: Danial Mehranfard; Gabriela Perez; Andres Rodriguez; Julia M Ladna; Christopher T Neagra; Benjamin Goldstein; Timothy Carroll; Alice Tran; Malav Trivedi; Robert C Speth Journal: J Renin Angiotensin Aldosterone Syst Date: 2021-07-05 Impact factor: 1.636